Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Announces Earnings Results

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) posted its earnings results on Friday. The company reported ($2.75) earnings per share (EPS) for the quarter, FiscalAI reports.

Lakewood-Amedex Biotherapeutics Stock Down 2.6%

Shares of Lakewood-Amedex Biotherapeutics stock traded down $0.06 during trading hours on Friday, reaching $2.27. 105,327 shares of the stock traded hands, compared to its average volume of 4,226,770. Lakewood-Amedex Biotherapeutics has a one year low of $1.66 and a one year high of $98.20. The company has a market capitalization of $5.38 million and a price-to-earnings ratio of -1.14. The business’s 50 day moving average is $3.37.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Wall Street Zen cut shares of Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Weiss Ratings began coverage on shares of Lakewood-Amedex Biotherapeutics in a report on Monday, July 20th. They issued a “sell (e-)” rating on the stock. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.